NanoViricides CEO talks lead drug asset’s potential as MPOX therapy
NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral.…
1,060€
-3,20%
Echtzeit-Aktienkurs NanoViricides
Bid:
Ask:
Nachrichten zur NanoViricides Aktie
NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX
NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients…
NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387,…
NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024,…
NanoViricides’ lead asset with broad spectrum efficacy represents paradigm shift: analysts
NanoViricides (NYSE-A:NNVC)’ broad spectrum drug candidate NV-387 could present “a new paradigm shift in viral therapy,” according to a new…
NanoViricides’ lead asset for broad spectrum efficacy represents paradigm shift: analysts
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…
NanoViricides’ lead asset for broad spectrum efficacy wins praise in industry reports
NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential…
NanoViricides spotlights lead drug candidates potential as COVID therapy
NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies...…
NanoViricides discusses lead program and next steps
NanoViricides (NYSE-A:NNVC), a leader in broad-spectrum antiviral nanomedicines, is advancing its development program for NV-387. This single drug has shown...…
NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of...…
NanoViricides hails the potential of NV-387 in combatting bird flu virus H5N1
NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, believes its drug NV-387 could be crucial in fighting the bird flu…
NanoViricides says antiviral drug candidate shows promise in protecting lungs against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its ultra-broad-spectrum antiviral drug candidate NV-387 demonstrated effectiveness in protecting lungs from...…
NanoViricides antiviral candidate may be first effective oral nanomedicine
NanoViricides (NYSE-A:NNVC) said its lead antiviral candidate, NV-387, was found to be highly active when taken orally, making potentially the first...…
NanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosing
NanoViricides (NYSE-A:NNVC) has unveiled additional positive data for its lead clinical-stage broad-spectrum antiviral agent NV-387, a desirable blood...…
NanoViricides CEO says lead asset NV-387 could be ‘holy grail’ of antiviral medicines
NanoViricides (NYSE-A:NNVC) is developing a first-in-class, broad-spectrum anti-viral agent NV-387 that it believes could revolutionize the treatment of...…
NanoViricides taps Aagami to seek out licensing and partnership opportunities
NanoViricides (NYSE-A:NNVC) announced that it has engaged Chicago-based life sciences consultancy firm Aagami for business development, specifically to seek...…
NanoViricides could generate ‘antiviral superdrug’ for multiple diseases, analysts believe
NanoViricides (NYSE-A:NNVC) has been awarded a ‘Buy’ rating and $6.50 price target by analysts at EF Hutton following the release…
Novel anti-viral could boost a US$3 bln market
New focus on viral respiratory infections especially highly transmissible RSV NanoViricides (NYSE-A:NNVC) (NV), a US company, owns a novel, multi-target,...…
NanoViricides reports strong antiviral activity of NV-387 against RSV
NanoViricides (NYSE-A:NNVC) has reported that its antiviral drug candidate NV-387 demonstrated significant efficacy against respiratory syncytial virus...…
NanoViricides shares gain as new data shows lead drug assets strong activity against RSV
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…
NanoViricides unveils new data showing lead drug asset’s strong activity against RSV
NanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity of its lead drug asset NV-387…
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
NanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad antiviral activity of its investigational therapeutic...…
NanoViricides to showcase lead drug asset’s progress at EF Hutton Annual Global Conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides to showcase lead drug asset’s progress at global conference
NanoViricides (NYSE-A:NNVC) announced that members of its leadership team will be attending the EF Hutton Annual Global Conference being held…
NanoViricides says lead asset shows antiviral activity against Smallpox and Mpox
NanoViricides (NYSE-A:NNVC) told investors that the ultra-broad antiviral activity spectrum of its lead drug asset NV-387 includes activity against the...…
NanoViricides drug asset shows ‘superior antiviral effects’ against Influenza A
NanoViricides (NYSE-A:NNVC) announced that its lead drug asset NV-387 has shown ultra-broad antiviral activity, including against Influenza A viruses. The...…
NanoViricides completes Phase 1 trial of lead asset NV-387
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…
NanoViricides completes Phase 1 trial for respiratory viral infection candidate
NanoViricides (NYSE-A:NNVC) announced that a Phase 1 trial of its investigational therapeutic NV-387 has been completed. The company, a leader…